Selumetinib in Cancers With BRAF Mutations

Exclusion Criteria

• •Estimated life expectancy \> 12 weeks
• •Patients with melanoma
• •Have received chemotherapy or radiotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C), or a targeted therapy within 2 weeks prior to entering the study
• •Have not recovered from adverse events due to agents previously administered (CTCAE v3 grade 1 or baseline)
• •Currently receiving other investigational agents
• •Known brain metastases, unless treated and stable off of corticosteroids for at least four weeks
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
• •Prior treatment with a selective inhibitor of RAF or MEK (e.g., RAF265); (note: prior sorafenib is allowed)
• •Uncontrolled intercurrent illness, including but not limited to:
• •* Clinically significant active infection
• •* Symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac arrhythmia other than atrial fibrillation
• •* Psychiatric illness/social situations that would limit compliance with study requirements
• •Refractory nausea or vomiting, swallowing disorder, or malabsorption syndrome that would interfere with swallowing or absorbing the study medication
• •Pregnant and/or breast-feeding women
• •Previous or concurrent malignancy, except for the following circumstances:
• •* Disease-free for at least three years and deemed by investigator to be at low risk for recurrence of that malignancy